Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will ...
– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...
"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors Chronic myelomonocytic leukemia ...
(RTTNews) - Cardiff Oncology, Inc. (CRDF) has presented new clinical data from an investigator-sponsored Phase 1 dose escalation trial evaluating onvansertib, a novel oral PLK1 inhibitor, in patients ...
(RTTNews) - Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biopharmaceutical company, on Monday announced the resumption of patient enrollment in the investigator-initiated Phase 1/2 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results